Χρηματοδότηση

COMPETITIVE FUNDING (2001 -2020)

• Immunex USA –Investigator Initiated study, Anti-TNF for membranous neprhropathy Prinicipal Investigator (P.I 120.000€ total including drug).
• General Secretarial for Research and Technology (GSTR), ΕPΕΑΕΚ (420.000 €)

Infrastructure for the Graduate Program, Molecular Basis of Human Disease. P.I

• Pythagoras (ΕPΕΑΕΚ,). Pathogenesis of lupus nephritis. P.I (100.000 €)
• FP-6 (AUTOCURE) Rheumatoid arthritis. Partner. (219.000 €).
• SYNERGASIA (GSRT) Autoinflammation, (P.I total: 792.000 €, personal 150.000 €).
• SYNERGASIA Inflammation and Atherosclerosis. Partner (110.000€)
• SYNERGASIAImmune tolerance. Partner (150.000 €).
• ARISTEIA (Autoimmune Search, GSRT, Autoimmunity (SLE) (P.I 332.000 €)
• IMI BTCure Rheumatoid arthritis and related diseases. Partner (328.000 €).
• Thalis (GSRT). Inflammation and dementia. Partner. (90.000 €)
• FOREUM (Found for Rhem Res). Next generation sequencing in SLE. (PI Total 300.000)
• SYSCID (IMI) 600.000 €
• ERC ADVANCED GRANT (ΡΙ 2.350.000 €)
• ΧΟΡΗΓΙΑ ΙΔΡ.ΩΝΑΣΗ - Β ΚΥΚΛΟΣ (20.000€)